Hanmi Pharm Co Ltd (128940) - Total Liabilities
Based on the latest financial reports, Hanmi Pharm Co Ltd (128940) has total liabilities worth ₩694.79 Billion KRW (≈ $470.85 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Hanmi Pharm Co Ltd - Total Liabilities Trend (2010–2024)
This chart illustrates how Hanmi Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 128940 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Hanmi Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of Hanmi Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
First Interstate BancSystem Inc
NASDAQ:FIBK
|
USA | $23.07 Billion |
|
Suzhou TZTEK Technology Co Ltd
SHG:688003
|
China | CN¥1.98 Billion |
|
Hengan International Group Company Limited
F:HGNC
|
Germany | €20.54 Billion |
|
Wockhardt Limited
NSE:WOCKPHARMA
|
India | Rs-46.57 Billion |
|
SolarEdge Technologies Inc
NASDAQ:SEDG
|
USA | $1.85 Billion |
|
Yifeng Pharmacy
SHG:603939
|
China | CN¥14.41 Billion |
|
Shenyang Jinshan Energy Co Ltd
SHG:600396
|
China | CN¥9.63 Billion |
|
GEK TERNA Holdings Real Estate Construction S.A
AT:GEKTERNA
|
Greece | €6.42 Billion |
Liability Composition Analysis (2010–2024)
This chart breaks down Hanmi Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 128940 stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.59 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hanmi Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hanmi Pharm Co Ltd (2010–2024)
The table below shows the annual total liabilities of Hanmi Pharm Co Ltd from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩780.09 Billion ≈ $528.66 Million |
-2.30% |
| 2023-12-31 | ₩798.46 Billion ≈ $541.10 Million |
-12.77% |
| 2022-12-31 | ₩915.36 Billion ≈ $620.33 Million |
-9.23% |
| 2021-12-31 | ₩1.01 Trillion ≈ $683.43 Million |
-3.97% |
| 2020-12-31 | ₩1.05 Trillion ≈ $711.66 Million |
-3.78% |
| 2019-12-31 | ₩1.09 Trillion ≈ $739.66 Million |
+21.01% |
| 2018-12-31 | ₩901.95 Billion ≈ $611.24 Million |
+3.85% |
| 2017-12-31 | ₩868.51 Billion ≈ $588.58 Million |
+0.70% |
| 2016-12-31 | ₩862.45 Billion ≈ $584.47 Million |
-11.80% |
| 2015-12-31 | ₩977.78 Billion ≈ $662.63 Million |
+120.18% |
| 2014-12-31 | ₩444.09 Billion ≈ $300.95 Million |
+6.25% |
| 2013-12-31 | ₩417.95 Billion ≈ $283.24 Million |
-1.95% |
| 2012-12-31 | ₩426.25 Billion ≈ $288.86 Million |
+4.08% |
| 2011-12-31 | ₩409.53 Billion ≈ $277.53 Million |
-3.03% |
| 2010-12-31 | ₩422.34 Billion ≈ $286.22 Million |
-- |
About Hanmi Pharm Co Ltd
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two activ… Read more